Relmada Therapeutics Stock Plunges 11% After Hiring A Development Chief For Its Cancer Pipeline
The decline followed a 25% monthly rally, with the drug developer preparing an application for its next bladder-cancer trials.
Relmada Therapeutics, which develops experimental medicines for bladder cancer and neurological disorders, plunged 11.4% to $3.73 in Monday trading, as of 11:06 AM ET, losing $51 million in market value. The move followed its appointment of a development chief for urology and urologic cancers, announced in an SEC filing Monday.
A Monthly Rally Meets A Reversal
Relmada Therapeutics was on pace Monday for its biggest one-day decline since July 16. Its market value stood at about $398 million in Monday trading.
Shares had gained 25% over the previous month. Even with that rally, they were down 13% for the year at Friday's close, compared with an 11% gain for the S&P 500.
A Bladder-Cancer Veteran Takes The Role
Jørn Skibsted Jakobsen, Relmada Therapeutics' new chief development officer, will oversee development across the pipeline. The company said in its appointment announcement that his experience includes leading the ADSTILADRIN bladder-cancer program at drugmaker Ferring Pharmaceuticals.
The company's lead experimental treatment, NDV-01, delivers gemcitabine and docetaxel chemotherapy into the bladder through a controlled-release formulation. It is in a mid-stage trial for cancer that has not invaded the bladder muscle. Relmada Therapeutics holds exclusive worldwide rights outside Israel, India and South Africa.
Thursday's results release included 18-month trial findings: 12 of 14 evaluable patients who had a complete response at 12 months and reached the later assessment still had a complete response, or 86%. In the subgroup whose disease had not responded to BCG treatment, that figure was 88%, or seven of eight patients.
Two patients who had not previously received BCG progressed to muscle-invasive cancer at the 15-month assessment. The company reported no severe treatment-related adverse events, treatment-related serious adverse events or treatment-related discontinuations.
The planned late-stage program, renamed SPECTRUM, retains two independent routes toward approval. “We expect to begin the SPECTRUM program upon IND clearance,” said Bipin Dalmia, chief business officer of Relmada Therapeutics, in the results release. An IND is an application to begin clinical testing.
Cash To Support The Trial Plans
Relmada Therapeutics recorded a third-quarter net loss of $13.9 million in its quarterly report submitted Thursday. The company has no medicines approved for sale and has generated no revenue.
Cash, cash equivalents and short-term investments totaled approximately $202.1 million as of September 30, 2026. Management expects that funding to support operations through 2029.
The other experimental medicine, sepranolone, has been evaluated in studies involving more than 335 participants. Relmada Therapeutics is finishing stability testing for its pre-filled syringe and expects to submit its clinical-testing application by year-end 2026, with a mid-stage Prader-Willi syndrome trial planned after clearance.
Relmada Therapeutics also expects to submit the NDV-01 clinical-testing application by year-end 2026. Its planned SPECTRUM trials depend on that application receiving clearance.
Sources
- Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer — Yahoo Finance
- Relmada Therapeutics Appoints Uro-Oncology Leader Jørn — globenewswire.com
- The company's filing (Relmada Therapeutics) — SEC filing
- Relmada Therapeutics — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR
- Relmada Therapeutics — earnings release (Form 8-K, Item 2.02), filed 2026-11-12 — SEC EDGAR